Turning Point Brands - Q3 2026 Earnings - TURNING POINT BRANDS INC

Financial Performance:

• Consolidated net sales rose 27% year-over-year to $151 million for Q3 2026, driven primarily by Modern Oral growth.
• Modern Oral gross sales surged 114% YoY and 8% sequentially; net sales increased 103% YoY and 9% sequentially.
• Modern Oral revenue now represents 49% of total company revenue, up from 31% in Q3 2025.
• Gross profit increased 21% to $85 million; gross margin stood at 56% (down 416 basis points from Q2, normalized for tariff refunds).
• SG&A expenses decreased nearly $2 million sequentially to $75 million as the company adjusted spending based on ROI.
• Adjusted EBITDA declined 41% YoY to $18 million due to strategic increases in sales and marketing investment.
• Adjusted EBT rose 21% sequentially to $2.2 million, supported by higher gross profit and lower SG&A.
• Free cash flow for the quarter was $3.5 million; ending cash balance was $251 million.
• The company repurchased $10 million of stock in Q3, maintaining a measured capital allocation approach.

Guidance and Future Outlook:

• Full-year 2026 Modern Oral net sales guidance remains $260–$270 million; gross sales guidance is $330–$350 million.
• Full-year adjusted EBITDA guidance is maintained at $70–$80 million.
• Expected effective income tax rate is between 23% and 26% on a go-forward basis.
• Management anticipates Q4 Modern Oral net sales to show sequential growth, though specific drivers include channel timing and holiday loading effects.
• 2027 is projected to mark the commencement of U.S. domestic manufacturing, a key driver for long-term profitability.
• Q4 CapitalEx is expected to be $1–$2 million (excluding Modern Oral projects), with an additional $3.5 million allocated for PMTA support.

Business Segments and Product Lines:

• Modern Oral: Accounts for $74 million in net revenue (103% YoY growth). Brands include "Free" (chain-focused, early innings) and "ALP" (independent/regional focus, transitioning to chains).
• Stokers Heritage: Net sales up 3% YoY to $39 million, driven by share growth in MSDs, partially offset by declining loose leaf tobacco sales.
• ZigZag: Net sales declined 15% YoY to $37 million; gross margin stable at 57%. Focus remains on rolling papers, cones, and wraps via cultural partnerships.
• Distribution Expansion: On track to increase chain store count by >70% in 2026. "Free" is deploying into national chains won earlier in the year; "ALP" is expanding in independent retailers and beginning national chain negotiations for the Spring 2027 reset.
• Product Innovation: "Free Labs" launching limited editions based on consumer feedback; "ALP New Frontier Collection" launched three requested flavors.

Market and Competitive Landscape:

• The nicotine pouch category is maturing, with smaller competitors expected to be "weeded out," favoring larger, well-distributed brands.
• Management views Free and ALP as the primary candidates to become "ubiquitously distributed" alongside existing market leaders.
• Chain accounts now hold the majority of category volume; securing placement in large regional and national chains is critical for long-term durability.
• Strategic partnerships, including the TKO deal, are being leveraged to increase in-store visibility and consumer engagement.

Risks and Challenges:

• Regulatory: Full U.S. manufacturing deployment is contingent on FDA PMTA approvals; timing depends on regulatory pathways and secondary submission strategies.
• Seasonality/Volume Timing: End-of-year volume shifts (buying/loading in December vs. January) create uncertainty for Q4 revenue recognition.
• Channel Opacity: ZigZag sales include a significant volume in "backstreet" channels (non-reporting independent shops), making data less transparent.
• Margin Pressure: Near-term EBITDA is suppressed by heavy upfront investments in distribution, marketing, and infrastructure to secure long-term market share.

Management Commentary and Tone:

• CEO David Glasek expressed strong confidence and excitement in his first call as CEO, citing a "transformational opportunity" to capture the shift from cigarettes to modern oral nicotine.
• Management tone is optimistic and strategic, emphasizing that current investments are building a "durable long-term annuity stream."
• Leadership highlighted a "reinforcing cycle of growth" where broader distribution drives trial, which fuels repeat purchases and further expansion.
• No M&A is currently planned; the strategy prioritizes organic growth to capture the billions in shifting revenue from traditional tobacco.

Analyst Questions and Answers:

• Q: Q4 Modern Oral guidance implies a flat or slight decrease; what is behind this? A: No change in trajectory; guidance reflects timing of channel loading and holiday uncertainty, not a lack of momentum.
• Q: Current inning for brick-and-mortar distribution? A: "Early innings" for both brands; Free is ahead in chain rollout, ALP is attacking independents and starting chain talks for 2027.
• Q: Timing of U.S. manufacturing? A: Dependent on FDA; company is upgrading facilities and preparing a secondary PMTA submission to list U.S. manufacturing without disrupting the primary application.
• Q: Velocity and sell-through trends? A: Encouraging; velocity improves with broader SKU assortments in stores; ALP's independent rollout is meeting or exceeding expectations.
• Q: 7-Eleven performance for ALP? A: Strong performance noted with high facings (14); management sees the brand as early in its lifecycle with significant runway.
• Q: EBITDA guidance range sensitivity? A: Wider range reflects the lower absolute EBITDA level where small timing variances or unusual items have a larger percentage impact on results.

Other Key Points:

• Management is utilizing a "flexible" approach to SG&A, scaling back investments with inadequate returns while maintaining discipline on capital deployment.
• The "Spring Reset" remains a critical timeline for negotiating new chain placements and rollouts.
• The company is leveraging its two-brand portfolio (Free and ALP) to cover diverse consumer needs and distribution channels, creating a competitive moat.
• A secondary PMTA pathway (PMTA-2) was utilized to allow U.S. manufacturing listing without derailing the primary FDA review process.